PRIMO 2023 | Differentiating between small cell and neuroendocrine prostate cancer

Ravi Madan, MD, National Cancer Institute, Bethesda, MD, comments on the pathological differences between small cell and neuroendocrine prostate cancer. Small cell prostate cancer, a rare, aggressive form of the cancer, develops from neuroendocrine cells of the prostate, and typically requires a platinum-based therapy. A lack of knowledge regarding neuroendocrine prostate cancer, which itself can be characterized as an adenocarcinoma with neuroendocrine features, may result in improper treatment. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.